Please login to the form below

Not currently logged in
Email:
Password:

orphan drugs

This page shows the latest orphan drugs news and features for those working in and with pharma, biotech and healthcare.

Malthus’ orphans

Malthus’ orphans

By and large, rare diseases and orphan drugs don’t lend themselves to the former or the latter. ... Life sciences companies that see orphan drugs and other diseases as their future might do well to consider the threat of Malthus’trap.

Latest news

More from news
Approximately 83 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • Drug R&D

    Healthcare terms - Drug R&D.

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    drugs - from Adalimumab to Rituximab - go off-patent and boost savings across eight European nations to 33.4bn over the next three years. ... What is surprising is that the whole of Europe is deeply concerned about the price of new medicines and how it

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Altogether 39 orphan drugs were approved in the US during 2016 and 14 in the EU (a mix of NME, BLA, NAS or old substances with a new use for an ... We expect the strong overall trend for more orphan drugs submitted to and approved by the FDA and the EMA

  • Shoring up the framework Shoring up the framework

    This first document, set out in a Q&A format, covers information on company location, with respect to centralised procedures and certain other activities, including the location of orphan designation holders ... Marketing authorisation holders for

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Under fire. Some observers feel that Germany and France provide relatively wide access to orphan drugs, certainly compared to England. ... Numbers game. The number of orphan drugs actually being approved in Europe is hard to quantify.

More from intelligence
Approximately 14 fully matching, plus 35 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Pharma Market Research Report - Predictions for 2016

    2016 will continue to see an increase in the number of requests for research projects investigating the market opportunity for rare disease and orphan drugs. ... Firstly, manufacturers of orphan drugs are awarded longer market exclusivity, reduced

  • Ashfield to present at the Orphan Drugs for Rare Diseases Summit

    Ashfield has a breadth of experience with orphan drugs and we are passionate about helping to improve the lives of people living with rare diseases. ... We are delighted to be sponsoring and presenting at the ‘ Orphan Drugs for Rare Diseases’ event 22

  • Ashfield to present at the Orphan Drugs for Rare Diseases Summit

    Ashfield has a breadth of experience with orphan drugs and we are passionate about helping to improve the lives of people living with rare diseases. ... We are delighted to be sponsoring and presenting at the ‘ Orphan Drugs for Rare Diseases’ event 22

  • Finding the familiar in Rare Disease

    Finding the familiar in Rare Disease. Inspired by World Rare Disease Day, WE Communication's Hugh Adams covers some of the challenges faced when considering Rare Disease communications. Estimates suggest that a so-called rare disease affects one in

  • Can rare diseases be a viable option for the pharma industry?

    Market research with many of the industry leaders involved with the development of orphan drugs has indicated the main influential drivers to pursuing an orphan drug approval as the reasons shown ... The necessary infrastructure, understanding of orphan

More from PMHub
Approximately 4 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics